mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer

Ribonucleotide reductase (RNR) is the key enzyme that catalyzes the production of deoxyribonucleotides (dNTPs) for DNA replication and it is also essential for cancer cell proliferation. As the RNR inhibitor, Gemcitabine is widely used in cancer therapies, however, resistance limits its therapeutic efficacy and curative potential. Here, we identified that mTORC2 is a main driver of gemcitabine resistance in non-small cell lung cancers (NSCLC). Pharmacological or genetic inhibition of mTORC2 greatly enhanced gemcitabine induced cytotoxicity and DNA damage. Mechanistically, mTORC2 directly interacted and phosphorylated RNR large subunit RRM1 at Ser 631. Ser631 phosphorylation of RRM1 enhanced its interaction with small subunit RRM2 to maintain sufficient RNR enzymatic activity for efficient DNA replication. Targeting mTORC2 retarded DNA replication fork progression and improved therapeutic efficacy of gemcitabine in NSCLC xenograft model in vivo. Thus, these results identified a mechanism through mTORC2 regulating RNR activity and DNA replication, conferring gemcitabine resistance to cancer cells.

• Publication year

  2021

• Venue

  Neoplasia

• Publication date

  2021-06-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.neo.2021.05.007PMID 34126361PMCID 8215139
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mre11 exonuclease activity removes the chain-terminating nucleoside analog gemcitabine from the nascent strand during DNA replication

  2020cited by this paper
• Mre11 exonuclease activity removes the chain-terminating nucleoside analog gemcitabine from the nascent strand during DNA replication.

  2020cited by this paper
• mTOR: Role in cancer, metastasis and drug resistance.

  2019cited by this paper
• DNA replication stress: oncogenes in the spotlight

  2019cited by this paper
• mTORC2-mediated PDHE1α nuclear translocation links EBV-LMP1 reprogrammed glucose metabolism to cancer metastasis in nasopharyngeal carcinoma

  2019cited by this paper
• Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer.

  2019cited by this paper
• Acetylation regulates ribonucleotide reductase activity and cancer cell growth

  2019cited by this paper
• The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2.

  2019cited by this paper
• Novel ATP-cone-driven allosteric regulation of ribonucleotide reductase via the radical-generating subunit

  2018cited by this paper
• Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex

  2018cited by this paper
• Replication Stress Shapes a Protective Chromatin Environment across Fragile Genomic Regions.

  2018cited by this paper
• Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

  2017cited by this paper
• mTOR Signaling in Growth, Metabolism, and Disease.

  2017cited by this paper
• mTORC1 signaling and the metabolic control of cell growth.

  2017cited by this paper
• MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling

  2017cited by this paper
• mTORC2 Promotes Tumorigenesis via Lipid Synthesis.

  2017cited by this paper
• mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT.

  2017cited by this paper
• Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells

  2016cited by this paper
• mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

  2016cited by this paper
• Sestrin 2 is a leucine sensor for the mTORC 1 pathway

  2016cited by this paper
• Sestrin2 is a leucine sensor for the mTORC1 pathway

  2016cited by this paper
• The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient

  2015cited by this paper
• RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.

  2015cited by this paper
• Multiple facets of histone variant H2AX: a DNA double-strand-break marker with several biological functions

  2015cited by this paper
• A gemcitabine sensitivity screen identifies a role for NEK9 in the replication stress response

  2014cited by this paper
• Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

  2014cited by this paper
• Hyperthermia inhibits recombination repair of gemcitabine-stalled replication forks.

  2014cited by this paper
• Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC.

  2013cited by this paper
• TORC2 signaling pathway guarantees genome stability in the face of DNA strand breaks.

  2013cited by this paper
• dNTP pools determine fork progression and origin usage under replication stress

  2012cited by this paper
• Genetic Polymorphism of XRCC1 Arg399Gln Is Associated With Survival in Non–Small-Cell Lung Cancer Patients Treated With Gemcitabine/Platinum

  2012cited by this paper
• Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

  2011cited by this paper
• mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis.

  2010cited by this paper
• Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

  2009cited by this paper
• Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients

  2008cited by this paper
• Enhanced subunit interactions with gemcitabine-5′-diphosphate inhibit ribonucleotide reductases

  2007cited by this paper
• Understanding ribonucleotide reductase inactivation by gemcitabine.

  2007cited by this paper

• Regulation of ferroptosis in colorectal cancer through therapeutic modulation and miRNA targeting

  2026cites this paper
• Enhancing the Nucleoside Analog Response with Translational Therapeutic Approaches to Overcome Resistance

  2026cites this paper
• Targeted metabolism creates possibilities for lung cancer treatment in the precision tumor era

  2026cites this paper
• RRM1 O-GlcNAcylation inhibition suppresses pancreatic cancer via TK1-mediated replication stress

  2025cites this paper
• Natural product Pulsatilla saponin D sensitizes BRCA-proficient ovarian cancers to PARP inhibitors through inhibiting homologous recombination repair.

  2025cites this paper
• Ribonucleotide reductases in cancer: Mechanisms, clinical progress, and prospects

  2025cites this paper
• The Role of PI3K/AKT/mTOR Signaling in Tumor Radioresistance and Advances in Inhibitor Research

  2025cites this paper
• BUB1B promotes gemcitabine resistance in lung adenocarcinoma and activates the PI3K/AKT signaling pathway.

  2025cites this paper
• DEAD/H-box RNA helicase 10 promotes pancreatic cancer cell proliferation via ribonucleotide reductase M2

  2025cites this paper
• ENO1-mediated deoxycytidine synthesis and gemcitabine resistance by stabilizing RRM2 in pancreatic cancer

  2025cites this paper
• LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein.

  2024cites this paper
• The mTORC2 signaling network: targets and cross-talks

  2024cites this paper
• Targeting UBE2T potentiates gemcitabine efficacy in pancreatic cancer by regulating pyrimidine metabolism and replication stress.

  2023cites this paper
• Targeting the biology of aging with mTOR inhibitors

  2023cites this paper
• Targeting CK2-mediated phosphorylation of p53R2 sensitizes BRCA-proficient cancer cells to PARP inhibitors

  2023cites this paper
• SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair

  2022cites this paper
• KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma

  2022cites this paper